comparemela.com

Latest Breaking News On - ஆன்டிபாடி காக்டெய்ல் - Page 5 : comparemela.com

From Powder in Sachets to Nasal Sprays - Indian Markets Swamped With COVID-19 Drugs

Covid-19: Zydus seeks DCGI nod to undertake clinical trials for monoclonal antibodies cocktail

URL copied Covid-19: Zydus seeks DCGI nod to undertake clinical trials for monoclonal antibodies cocktail Zydus Cadila on Thursday said it is seeking permission from Drugs Controller General of India (DCGI) to initiate human clinical trials for monoclonal antibodies cocktail for treatment of COVID-19. “Zydus is currently seeking permission to initiate phase 1/3 human clinical trials from the DCGI… ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID 19,” Cadila Healthcare said in a regulatory filing. Cadila Healthcare is the listed entity of the group. ZRC-3308 has been found to be safe and well tolerated in animal toxicology studies.

Cipla Lauches Antibody Cocktail For Treating Covid-19; Shares Subdued

The second batch of the antibody cocktail will be made available by mid-June, Cipla added Cipla and Roche India have launched Roche India s antibody drug cocktail in India for treating mild to moderate COVID-19 cases. Roche India and Cipla today announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India, Cipla said in a regulatory filing to the stock exchanges. The second batch of the antibody cocktail will be made available by mid-June, Cipla added. Umang Vohra, Managing Director and Global CEO, Cipla said, We are guided by our strong sense of responsibility to address unmet patient need and look forward to leveraging our solid marketing and distribution strengths in India to provide broader, equitable access to this innovative treatment option in the country .

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.